+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Urinary Tract Infection (UTI) Treatment Market 2021-2025

  • ID: 5232281
  • Report
  • November 2021
  • Region: Global
  • 120 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the urinary tract infection (UTI) treatment market and it is poised to grow by $ 2.66 bn during 2021-2025, progressing at a CAGR of 4.71% during the forecast period. The report on the urinary tract infection (UTI) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the relation of UTI with several other factors leading to rising incidence rate of UTI and rising cases of hospital-acquired UTI.

The urinary tract infection (UTI) treatment market analysis includes the type segment and geographic landscape.

The urinary tract infection (UTI) treatment market is segmented as below:


By Type

  • Uncomplicated UTI
  • Complicated UTI

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising use of urinary catheters as one of the prime reasons driving the urinary tract infection (UTI) treatment market growth during the next few years.

The report on urinary tract infection (UTI) treatment market covers the following areas:

  • Urinary tract infection (UTI) treatment market sizing
  • Urinary tract infection (UTI) treatment market forecast
  • Urinary tract infection (UTI) treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading urinary tract infection (UTI) treatment market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. Also, the urinary tract infection (UTI) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Disease type

  • Market segments
  • Comparison by Disease type
  • Uncomplicated UTI - Market size and forecast 2020-2025
  • Complicated UTI - Market size and forecast 2020-2025
  • Market opportunity by Disease type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity By Geographical Landscape
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Disease type - Market share 2020-2025 (%)
  • Comparison by Disease type
  • Uncomplicated UTI - Market size and forecast 2020-2025 ($ million)
  • Uncomplicated UTI - Year-over-year growth 2020-2025 (%)
  • Complicated UTI - Market size and forecast 2020-2025 ($ million)
  • Complicated UTI - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Disease type
  • Customer landscape
  • Market share By Geographical Landscape 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity By Geographical Landscape ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Key customers
  • Abbott Laboratories - Segment focus
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product and service
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Key customers
  • AbbVie Inc. - Segment focus
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product and service
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Key customers
  • AstraZeneca Plc - Segment focus
  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Business segments
  • Boehringer Ingelheim International GmbH - Key offerings
  • Boehringer Ingelheim International GmbH - Key customers
  • Boehringer Ingelheim International GmbH - Segment focus
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Key customers
  • Cipla Inc. - Segment focus
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Key customers
  • Merck and Co. Inc. - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • SHIONOGI Co. Ltd. - Overview
  • SHIONOGI Co. Ltd. - Business segments
  • SHIONOGI Co. Ltd. - Key offerings
  • SHIONOGI Co. Ltd. - Key customers
  • SHIONOGI Co. Ltd. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
The publisher recognizes the following companies as the key players in the global urinary tract infection (UTI) treatment market: Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is rising use of urinary catheters.`

According to the report, one of the major drivers for this market is the relation of UTI with several other factors leading to rising incidence rate of UTI.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.
Note: Product cover images may vary from those shown